摘要
耐药性仍是大多数以血管内皮生长因子通路(肿瘤血管再生的关键调节物质)禁制因素治疗的患者一直以来的挑战。临床前模型在鉴别多种复杂康血管再生治疗失败机制起到了很显著的作用。但是仍存在关于优化研究耐药机制方法的问题,这有助在临床上对选择性或者联合治疗方案做出相关的选择。抗血管增生治疗失败的原因可能在于肿瘤脉管系统、肿瘤自身或者两者,且定义性的临床前方法是多种多样的,很少拿来作以比较。我们对临床前那些用来检测血管内皮生长因子通路禁制因素的耐药性进行了文献检索,从400多篇文献根据机制研究起始点而治疗失败方向挑选出109篇。我们发现抵制的定义是广泛的且不一致的,只与一小部分试剂相关,并且大多数来源于那些在临床上未表达出相关疾病状态或者进程的体内外方法学。综上,本文的分析强调了在临床前设置和改善的方法学的需要中研究肿瘤微环境禁制因素的挑战,为有助于使失败治疗质化或者量化,进一步的鉴别出那些将帮助患者预测选择性治疗方案的机制。
关键词: 血管内皮生长因子;耐药性;转移;小鼠模型;遗传工程小鼠模型;同源;常位
图形摘要
Current Drug Targets
Title:The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Volume: 17 Issue: 15
Author(s): Michalis Mastri, Spencer Rosario, Amanda Tracz, Robin E. Frink, Rolf A. Brekken, John M. L. Ebos
Affiliation:
关键词: 血管内皮生长因子;耐药性;转移;小鼠模型;遗传工程小鼠模型;同源;常位
摘要: Drug resistance remains an ongoing challenge for the majority of patients treated with inhibitors of the vascular endothelial growth factor (VEGF) pathway, a key regulator of tumor angiogenesis. Preclinical models have played a significant role in identifying multiple complex mechanisms of antiangiogenic treatment failure. Yet questions remain about the optimal methodology to study resistance that may assist in making clinically relevant choices about alternative or combination treatment strategies. The origins of antiangiogenic treatment failure may stem from the tumor vasculature, the tumor itself, or both together, and preclinical methods that define resistance are diverse and rarely compared. We performed a literature search of the preclinical methodologies used to examine resistance to VEGF pathway inhibitors and identified 109 papers from more than 400 that use treatment failure as the starting point for mechanistic study. We found that definitions of resistance are broad and inconsistent, involve only a small number of reagents, and derive mostly from in vitro and in vivo methodologies that often do not represent clinically relevant disease stages or progression. Together, this literature analysis highlights the challenges of studying inhibitors of the tumor microenvironment in the preclinical setting and the need for improved methodology to assist in qualifying (and quantifying) treatment failure to identify mechanisms that will help predict alternative strategies in patients.
Export Options
About this article
Cite this article as:
Michalis Mastri, Spencer Rosario, Amanda Tracz, Robin E. Frink, Rolf A. Brekken, John M. L. Ebos , The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy, Current Drug Targets 2016; 17 (15) . https://dx.doi.org/10.2174/1389450117666151209123544
DOI https://dx.doi.org/10.2174/1389450117666151209123544 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Nerve Growth Factor in Neurological and Non-Neurological Diseases: Basic Findings and Emerging Pharmacological Prospectives
Current Pharmaceutical Design Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry